SLN360
Silence Therapeutics
[]
silence therapeutics presents new analysis from sln360 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting - neuro central via brainsights for ios 
Stay on top of the latest Brain & Neuroscience research & news from all the best sources delivered directly to your iPhone/iPad